Jade Biosciences (JBIO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $13.47, -2.11% vs the prior close of $13.76.
- Volume 980.98K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
JBIO dips 2.1% to $13.47. Closed at $13.47, -2.11% vs the prior close of $13.76. Day range $13.03–$14.10, opened at $13.78.
JBIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — JBIO dips 2.1% to $13.47
- Closed at $13.47, -2.11% vs the prior close of $13.76. Day range $13.03–$14.10, opened at $13.78.
- Volume was 980.98K shares, 1.1x its 50-day average of 914.17K.
- Price is -25.8% vs its 50-day average ($18.15) and -26.0% vs its 200-day average ($18.21).
- 52-week range $8.36–$28.00; today's close sits at 26% of that range, 51.9% below the 52-week high.
Oct 15, 2026 — JBIO rises 2.4% to $13.76
- Closed at $13.76, +2.38% vs the prior close of $13.44. Day range $13.45–$14.18, opened at $13.54.
- Volume was 1.04M shares, 1.1x its 50-day average of 918.69K.
- Price is -24.9% vs its 50-day average ($18.33) and -24.5% vs its 200-day average ($18.22).
- 52-week range $8.36–$28.00; today's close sits at 27% of that range, 50.9% below the 52-week high.
Oct 14, 2026 — JBIO ends flat (+0.1%) to $13.44
- Closed at $13.44, +0.15% vs the prior close of $13.42. Day range $12.85–$13.65, opened at $13.22.
- Volume was 1.17M shares, 1.3x its 50-day average of 928.99K.
- Price is -27.3% vs its 50-day average ($18.49) and -26.3% vs its 200-day average ($18.23).
- 52-week range $8.36–$28.00; today's close sits at 26% of that range, 52.0% below the 52-week high.
Oct 13, 2026 — JBIO slides 4.1% to $13.42
- Closed at $13.42, -4.14% vs the prior close of $14.00. Day range $13.35–$14.23, opened at $14.00.
- Volume was 1.33M shares, 1.5x its 50-day average of 915.43K.
- Price is -28.0% vs its 50-day average ($18.64) and -26.4% vs its 200-day average ($18.24).
- 52-week range $8.36–$28.00; today's close sits at 26% of that range, 52.1% below the 52-week high.
Oct 12, 2026 — JBIO dips 2.7% to $14.00
- Closed at $14.00, -2.71% vs the prior close of $14.39. Day range $13.82–$14.44, opened at $14.33.
- Volume was 1.36M shares, 1.5x its 50-day average of 900.32K.
- Price is -25.4% vs its 50-day average ($18.76) and -23.3% vs its 200-day average ($18.26).
- 52-week range $8.36–$28.00; today's close sits at 29% of that range, 50.0% below the 52-week high.
Oct 9, 2026 — JBIO rises 1.7% to $14.39, 3 up days in a row
- Closed at $14.39, +1.70% vs the prior close of $14.15. Day range $14.00–$14.81, opened at $14.16.
- Volume was 735.60K shares, 0.8x its 50-day average of 894.26K.
- Price is -23.8% vs its 50-day average ($18.87) and -21.2% vs its 200-day average ($18.27).
- 52-week range $8.36–$28.00; today's close sits at 31% of that range, 48.6% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — JBIO rises 2.8% to $14.15 on 1.9x normal volume
- Closed at $14.15, +2.76% vs the prior close of $13.77. Day range $13.18–$14.15, opened at $13.58.
- Volume was 1.67M shares, 1.9x its 50-day average of 873.59K — unusually heavy trading.
- Price is -25.5% vs its 50-day average ($18.99) and -22.6% vs its 200-day average ($18.28).
- 52-week range $8.36–$28.00; today's close sits at 29% of that range, 49.5% below the 52-week high.
Oct 7, 2026 — JBIO rises 2.7% to $13.77
- Closed at $13.77, +2.68% vs the prior close of $13.41. Day range $13.08–$14.14, opened at $13.19.
- Volume was 951.30K shares, 1.1x its 50-day average of 870.08K.
- Price is -27.9% vs its 50-day average ($19.09) and -24.7% vs its 200-day average ($18.30).
- 52-week range $8.36–$28.00; today's close sits at 28% of that range, 50.8% below the 52-week high.
Oct 6, 2026 — JBIO slides 4.7% to $13.41, a 6-month low
- Closed at $13.41, -4.69% vs the prior close of $14.07. Day range $13.15–$14.34, opened at $14.20.
- Volume was 493.90K shares, 0.6x its 50-day average of 888.51K — lighter than usual.
- Price is -30.2% vs its 50-day average ($19.21) and -26.8% vs its 200-day average ($18.31).
- 52-week range $8.36–$28.00; today's close sits at 26% of that range, 52.1% below the 52-week high.
Oct 5, 2026 — JBIO dips 0.4% to $14.07
- Closed at $14.07, -0.35% vs the prior close of $14.12. Day range $13.79–$14.70, opened at $14.21.
- Volume was 607.10K shares, 0.7x its 50-day average of 890.06K.
- Price is -27.2% vs its 50-day average ($19.34) and -23.2% vs its 200-day average ($18.32).
- 52-week range $8.20–$28.00; today's close sits at 30% of that range, 49.8% below the 52-week high.
Oct 2, 2026 — JBIO rises 2.5% to $14.12
- Closed at $14.12, +2.54% vs the prior close of $13.77. Day range $13.31–$14.17, opened at $13.86.
- Volume was 1.11M shares, 1.3x its 50-day average of 875.58K.
- Price is -27.4% vs its 50-day average ($19.46) and -23.0% vs its 200-day average ($18.33).
- 52-week range $8.16–$28.00; today's close sits at 30% of that range, 49.6% below the 52-week high.
JBIO latest news & SEC filings
Every SEC filing by or about JBIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$55.77M (prior year -$32.13M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.76 (prior year -$0.86) (loss narrowed vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 17, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Jun 26, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 26, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jun 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade JBIO
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 6, 2026, Jan 5, 2026. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.33% (largest 12.2%).
- Liquidity: about 944.27K shares (≈$12.72M) trade per day on average.
- 52-week position: $13.47 vs a range of $8.36–$28.00 (26% of the range).
- Dividends: last ex-dividend date Apr 29, 2025 ($2.4/share); 0 payments in the past 12 months.
- Splits: 1:35 on Apr 29, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 30, 2026; 10-Q Aug 10, 2026; 8-K Aug 10, 2026.
- Share count: 63.60M shares outstanding (Aug 3, 2026), +94.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
JBIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 13.78 | 14.10 | 13.03 | 13.47 | 980.98K |
| Oct 15, 2026 | 13.54 | 14.18 | 13.45 | 13.76 | 1.04M |
| Oct 14, 2026 | 13.22 | 13.65 | 12.85 | 13.44 | 1.17M |
| Oct 13, 2026 | 14.00 | 14.23 | 13.35 | 13.42 | 1.33M |
| Oct 12, 2026 | 14.33 | 14.44 | 13.82 | 14.00 | 1.36M |
| Oct 9, 2026 | 14.16 | 14.81 | 14.00 | 14.39 | 735.60K |
| Oct 8, 2026 | 13.58 | 14.15 | 13.18 | 14.15 | 1.67M |
| Oct 7, 2026 | 13.19 | 14.14 | 13.08 | 13.77 | 951.30K |
| Oct 6, 2026 | 14.20 | 14.34 | 13.15 | 13.41 | 493.90K |
| Oct 5, 2026 | 14.21 | 14.70 | 13.79 | 14.07 | 607.10K |
| Oct 2, 2026 | 13.86 | 14.17 | 13.31 | 14.12 | 1.11M |
| Oct 1, 2026 | 13.97 | 14.57 | 13.59 | 13.77 | 1.07M |
| Sep 30, 2026 | 14.43 | 14.74 | 13.95 | 14.05 | 930.90K |
| Sep 29, 2026 | 14.35 | 14.65 | 13.77 | 14.18 | 627.50K |
| Sep 28, 2026 | 14.29 | 14.70 | 14.08 | 14.35 | 598.60K |
| Sep 25, 2026 | 14.81 | 15.20 | 14.39 | 14.42 | 525.80K |
| Sep 24, 2026 | 14.59 | 15.06 | 14.45 | 14.73 | 1.05M |
| Sep 23, 2026 | 16.64 | 16.64 | 14.58 | 14.71 | 1.46M |
| Sep 22, 2026 | 16.92 | 17.16 | 16.60 | 16.76 | 643.90K |
| Sep 21, 2026 | 17.12 | 17.67 | 16.49 | 16.74 | 528.80K |
About Jade Biosciences
Jade Biosciences (JBIO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1798749.
JBIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Christopher W. Cain | Director | Jun 11, 2026 |
| Eric Dobmeier | Director | Jun 11, 2026 |
| Mark Eisner | Director | Jun 26, 2026 |
| Funds Management Llc Fairmount | Director | Jun 11, 2026 |
| Healthcare Co-Invest Iv L.P. Fairmount | Director | Jun 11, 2026 |
| Healthcare Fund Ii L.P. Fairmount | Director | Jun 11, 2026 |
| Tom Frohlich | Chief Executive Officer | Feb 13, 2026 |
| Peter Evan Harwin | Director | Jun 11, 2026 |
| Tomas Kiselak | Director | Jun 11, 2026 |
| Lawrence Otto Klein | Director | Jun 11, 2026 |
| Erin Lavelle | Director | Jun 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Elizabeth Balta | See Remarks | Feb 13, 2026 |
| Bradford D. Dahms | Chief Financial Officer | Feb 13, 2026 |
| Tom Frohlich | Chief Executive Officer | Feb 13, 2026 |
| Andrew James King | See Remarks | Feb 13, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
JBIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-127.41M | -3.19 | $-94.69M |
| Dec 31, 2024 | — | $-69.63M | -2.44 | $-71.20M |
| Dec 31, 2023 | — | $-75.52M | -2.87 | $-56.78M |
| Dec 31, 2022 | — | $-51.51M | -2.10 | $-39.12M |
| Dec 31, 2021 | — | $-22.96M | -1.87 | $-27.40M |
Latest balance sheet: total assets $472.11M, total liabilities $32.20M, cash $107.25M (as of Jun 30, 2026).
JBIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $21.73 |
| May 7, 2026 | 8-K Item 2.02 (results) | $24.22 |
| Mar 6, 2026 | 8-K Item 2.02 (results) | $14.05 |
| Jan 5, 2026 | 8-K Item 2.02 (results) | $13.12 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $10.70 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $7.33 |
| May 14, 2025 | 8-K Item 2.02 (results) | $7.55 |
| May 1, 2025 | 8-K Item 2.02 (results) | $10.00 |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Mar 25, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
| Aug 14, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on JBIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.